Abstract
Sphingolipid metabolites are critical to the regulation of a number of fundamental biological processes including cancer. Whereas ceramide and sphingosine mediate and trigger apoptosis or cell growth arrest, sphingosine 1- phosphate promotes proliferation, cell survival and angiogenesis. The delicate equilibrium between the intracellular levels of each of these sphingolipids is controlled by the enzymes that either produce or degrade these metabolites. Sphingosine kinase-1 is a crucial regulator of this two-pan balance, because it produces the pro-survival and pro-angiogenic sphingosine 1-phosphate and decreases the amount of both ceramide and sphingosine, the pro-apoptotic sphingolipids. Moreover, its gene is oncogenic, its mRNA is overproduced in several solid tumors, its overexpression protects cells from apoptosis, and its activity is down-regulated by anti-cancer treatments. Therefore, the sphingosine kinase-1/sphingosine 1-phosphate signaling pathway appears to be a target of interest for therapeutic manipulation.
Keywords: Antagonists, &, inhibitors, ceramide, sphingolipids, sphingosine, sphingosine kinase-1, sphingosine 1-phosphate, therapeutic antibody
Current Molecular Pharmacology
Title: Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Volume: 3
Author(s): Olivier Cuvillier, Isabelle Ader, Pierre Bouquerel, Leyre Brizuela, Bernard Malavaud, Catherine Mazerolles and Pascal Rischmann
Affiliation:
Keywords: Antagonists, &, inhibitors, ceramide, sphingolipids, sphingosine, sphingosine kinase-1, sphingosine 1-phosphate, therapeutic antibody
Abstract: Sphingolipid metabolites are critical to the regulation of a number of fundamental biological processes including cancer. Whereas ceramide and sphingosine mediate and trigger apoptosis or cell growth arrest, sphingosine 1- phosphate promotes proliferation, cell survival and angiogenesis. The delicate equilibrium between the intracellular levels of each of these sphingolipids is controlled by the enzymes that either produce or degrade these metabolites. Sphingosine kinase-1 is a crucial regulator of this two-pan balance, because it produces the pro-survival and pro-angiogenic sphingosine 1-phosphate and decreases the amount of both ceramide and sphingosine, the pro-apoptotic sphingolipids. Moreover, its gene is oncogenic, its mRNA is overproduced in several solid tumors, its overexpression protects cells from apoptosis, and its activity is down-regulated by anti-cancer treatments. Therefore, the sphingosine kinase-1/sphingosine 1-phosphate signaling pathway appears to be a target of interest for therapeutic manipulation.
Export Options
About this article
Cite this article as:
Cuvillier Olivier, Ader Isabelle, Bouquerel Pierre, Brizuela Leyre, Malavaud Bernard, Mazerolles Catherine and Rischmann Pascal, Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting, Current Molecular Pharmacology 2010; 3 (2) . https://dx.doi.org/10.2174/1874467211003020053
DOI https://dx.doi.org/10.2174/1874467211003020053 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design HSP60 as a Drug Target
Current Pharmaceutical Design LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling
Current Medicinal Chemistry Expression of Fucosyltransferases Contributes to Melanoma Invasive Phenotype
Medicinal Chemistry The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Radiopharmaceutical Tracking of Particles Injected into Tumors: A Model to Study Clearance Kinetics
Current Drug Delivery Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Mini-Reviews in Medicinal Chemistry